



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

Stock Code 股份代碼 : 1061

Admission of Product to the PRC National Drug List for Reimbursement

Beifuxin Newly Listed and the Other Three Products Remain on the List

Hong Kong, 21 August 2019 – Essex Bio-Technology Limited (“EssexBio” or the “Group”, Stock code: 1061) today is pleased to announce that Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) Gel (Product series: Beifuxin) has been newly admitted to the latest National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (“NDL”) issued by National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China on 20 August 2019, whilst the other three bio-pharmaceutical products that were previously included in 2017 NDL remain to be listed.

Details of the Group’s listed bio-pharmaceutical products are set out below:

Product series	Product form	Common name	Status
Beifushu	Eye Drops	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 444)
Beifushu	Eye Gel	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 444)
Beifuji	Lyophilized Powder	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 447)
Beifuxin	Gel	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 447)

The Board of Directors believe that the inclusion of Beifuxin, the largest turnover contributor of the Company, into NDL will further accelerate the expansion of distribution network of the Group’s flagship bio-pharmaceutical products in PRC and provide a strong impetus for organic growth in the immediate future.

About EssexBio

Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having five commercialised biologics marketed in China since 1998.

The products of the Company and its 3rd party products are prescribed for the treatment of wound healing and diseases in Ophthalmology & Dermatology, which are marketed and sold through more than 6,900 hospitals and managed directly by its 42 regional sales offices in China.

Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.

For enquiries, please contact Ms. Lin Xiaoyan of Zhixin Investor Relations Consultant Limited at 86 (755) 8323 9767 / E-mail: Linxiaoyan@zhixincaijing.com.